Preferred and alternative treatment options(in no special order) for hospitalised patients with moderate community-acquired pneumonia (C4)
| Preferred# | Alternative¶ |
| Penicillin G±macrolide+ | Levofloxacin§ |
| Aminopenicillin±macrolide+,§ | Moxifloxacin§,ƒ |
| Aminopenicillin/β-lactamase inhibitor§±macrolide+ | |
| Nonantipseudomonal cephalosporin II or III±macrolide+ |
#: in regions with low pneumococcal resistance rates; ¶: in regions with increased pneumococcal resistance rates or major intolerance to preferred drugs; +: new macrolides preferred to erythromycin; §: can be applied as sequential treatment using the same drug; ƒ: within the fluoroquinolones, moxifloxacin has the highest anti-pneumococcal activity. Experience with ketolides is limited, but they may offer an alternative when oral treatment is adequate. For recommended dosages see Appendix 3.